Cardiodiabesity
Article
New Evernorth EnReachRx model expands its suite of GLP-1 solutions, works to improve patient outcomes and drive value
Read More
Report
Pharmacy in Focus: Navigating GLP-1 cost, demand and sustainability
With demand and utilization expanding, comprehensive clinical support and cost-management strategies are crucial to ensuring accessibility and safeguarding health care budgets.
Read More
Report
Research: Addressing cardiodiabesity at the household level could lower cost trend
Research suggests that combatting cardiodiabesity at the family and household level could further improve health outcomes and lower costs.
Read More
Report
Study: Cardiodiabesity prevention key to improving health outcomes and lowering costs
The Evernorth Research Institute analyzed aggregated and anonymized data of almost 5 million insured individuals to understand the prevalence of "cardiodiabesity" — a condition which encompasses cardi...
Read MoreReport
Study: Progression of cardiodiabesity increases care utilization and costs
November 25, 2024
The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.
Article
Understanding cardiodiabesity in women
As employers strive to maintain a healthy and productive workforce, addressing and understanding the prevalence of cardiodiabesity in women is critical.
Read More